The global oncology drugs industry experienced significant growth during the past five years and is expected to continue that momentum to reach an estimated $100.6 billion in 2018.
Lucintel, a leading global
Management Consulting and market research firm, has analyzed the global oncology drugs industry and presents its findings in “
Global Oncology Drugs Industry 2013-2018: Trend, Profit, and Forecast Analysis.” The industry comprises firms primarily engaged in the development, manufacture, and marketing of oncology drugs.
Lucintel’s study of the oncology drugs industry includes all classes of drugs that are used as an anti-cancer drug for the treatment of cancer such as lung cancer, mouth cancer, colorectal cancer, skin cancer, kidney cancer, and all such other types of cancer, which are marketed and distributed as an oncology drugs.
North America dominates this industry with more than one-third of the market share. Roche Holding Ltd., Novartis AG, Astra Zeneca Plc, Eli Lilly & Co., and Sanofi SA are the major industry players. A combination of factors such as technology innovations, medical insurance coverage, aging population, and changing lifestyles are seen to affect market dynamics significantly. The industry has seen a number of recent changes including growing competition, rise in merger and acquisition activities, increased cancer health insurance coverage, and an increasing amount of foreign direct investment.
As per the study, aging population, changing lifestyles, more effective diagnosing, unhealthy eating habits, and an increasing incidence of chronic diseases across the entire global population will provide growth opportunities for the oncology drugs industry players.
This study provides an overview of the global oncology drugs industry and tracks industry performance in four geographic regions. The report studies manufacturers and distributors of oncology drugs, providing a five-year annual trend analysis that highlights market size, profit and cost structure for North America, Europe, Asia Pacific (APAC), and the Rest of the World (ROW). The report also provides a forecast, addressing market opportunities for next five years for each of these regions.
For a detailed table of contents and pricing information on this timely, insightful report, contact Lucintel at +1-972-636-5056 or via email at helpdesk@lucintel.com. Lucintel provides cutting-edge decision support services that facilitate critical decisions with greater speed, insight, and cost efficiency. To learn more, visit www.lucintel.com.